|Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.||
Antidepressants and the Risk of Suicidal Behaviors
The use of antidepressants, particularly SSRIs, in pediatric populations has attracted much controversy over the past year. This study, a "matched case control study of patients treated in UK general practices using the UK General Practice Research Database" included 160,000 users of 4 antidepressant drugs (amitriptyline, fluoxetine, paroxetine, and dothiepin).
The study measured the "frequency of first-time exposure to [these 4 drugs] of patients with a recorded diagnosis of first-time nonfatal suicidal behavior or suicide compared with comparable patients who did not exhibit suicide behavior."
The study found that "the risk of suicidal behavior after starting antidepressant treatment is similar among [the four drugs]", and that the risk is elevated in the first month after beginning treatment, "especially during the first 1 to 9 days."
|home spotlight commentary research events news about contact links archives|